Rajan Bajracharya Selected Research

bimekizumab

2/2024	Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL.
11/2023	Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study.
1/2023	Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE).
1/2023	Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL).
12/2022	Safety and Efficacy of Bimekizumab in Patients With Active Psoriatic Arthritis: Three-Year Results From a Phase IIb Randomized Controlled Trial and Its Open-Label Extension Study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Rajan Bajracharya Research Topics

Disease

5	Psoriatic Arthritis 02/2024 - 12/2022
3	Psoriasis (Pustulosis Palmaris et Plantaris) 02/2024 - 01/2023
2	Necrosis 02/2024 - 01/2023
2	Altitude Sickness (Mountain Sickness) 01/2008 - 01/2006
1	Mycoses (Diseases, Fungus) 01/2023

Drug/Important Bio-Agent (IBA)

5	bimekizumabIBA 02/2024 - 12/2022
2	Antirheumatic Agents (DMARD)IBA 11/2023 - 01/2023
2	Interleukin-17 (Interleukin 17)IBA 01/2023 - 01/2023
2	Acetazolamide (Diamox)FDA LinkGeneric 01/2008 - 01/2006